Accueil   Diary - News   All news ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia

ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia

ERYTECH NEWSLETTERERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it has reached full patient enrollment in the Phase 2b trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of acute myeloid leukemia (AML).

 

 

Read the press release